Overview


The Nanobodies Market is the global industry focused on the development, production, and commercialization of nanobodies, small, single-domain antibodies derived from camelids for diagnostics, therapeutics, and research applications. Driven by their high stability, specificity, and cost-effective production, the market is expanding rapidly across the biotechnology, pharmaceutical, and healthcare sectors.

According to FutureWise analysis, the Nanobodies market in 2026 is US$0.74 billion and is expected to reach US$2.46 billion by 2036 at a CAGR of 12.76%. The nanobodies market is experiencing rapid growth due to their unique properties, such as small size, high stability, and strong binding affinity. The significant growth in nanobody use underscores their growing acceptance in therapeutic and diagnostic applications. These tiny antibody fragments offer distinct advantages, including improved tissue penetration, greater stability, and cost-effective production. As a result, pharmaceutical companies and research institutions are investing heavily in the development of nanobody-based drugs.

Growth Drivers:

  • High specificity and stability of nanobodies compared to traditional antibodies.
  • Increasing use in diagnostics and targeted therapies for cancer, infectious, and autoimmune diseases.
  • Rising investment in biopharmaceutical research and development.
  • Cost-effective production and easier manufacturing processes.
  • Growing demand for personalized medicine and advanced biologics.

Key Trends:

  • Rising adoption of nanobody-based therapeutics in cancer and immunotherapy.
  • Growing use of rapid diagnostic tests and point-of-care applications.
  • Integration of nanobodies in antibody-drug conjugates (ADCs) and bi-specific therapies.
  • Increasing collaborations between biotech firms and research institutes for nanobody development.
  • Expansion of nanobody applications beyond healthcare, including veterinary and environmental testing

Market Segmentation and Key Players:

The Nanobodies Market is segmented by product type (mono-specific and multi-specific nanobodies), indication (oncology, autoimmune, infectious, and other diseases), distribution channel (hospital, retail, and online pharmacies), and region (North America, Europe, Asia-Pacific, and others). Comprehensive segmentation details are provided in the Segmentation section below.

Major companies operating in the Nanobodies Market include Sanofi and Merck.KGaA, and GenScript.

Research Methodology:

The Nanobodies Market research by FutureWise Research combines both secondary and primary data collection, starting with extensive analysis of existing industry sources and publications, followed by insights gathered from key stakeholders to estimate market size and future growth. The methodology includes systematic market breakdown and data triangulation to ensure accuracy, along with clearly defined assumptions for forecasts. It also uses analytical tools like Porter’s Five Forces and PESTEL to assess competitive dynamics and external factors, helping deliver a comprehensive, data-driven view of market trends, segmentation, and opportunities

  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Shire Plc
  • Merck KGaA
  • AbbVie, Inc.
  • C.H. Boehringer Sohn AG & Ko. KG.
  • Sanofi
  • AlpalifeB Inc
  • GenScript
  • GeneMedi
  • Numab Therapeutics
  • Proteintech Group, Inc.
  • Confo Therapeutics
  • GT Biopharma, Inc.
  • CUSABIO TECHNOLOGY LLC

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Narcolepsy Market:

Novo Nordisk A/S

  • Although Novo Nordisk is not directly involved in narcolepsy therapies, it maintains a strong position in the broader central nervous system (CNS) sector through significant investments in research and development (R&D). These investments include expansions related to its obesity and diabetes pipelines, which indirectly enhance its potential for developing future neurological treatments. In early 2024, the company completed the acquisition of fill-finish facilities from Novo Holdings, expanding its sterile manufacturing capabilities in Italy, Belgium, and Indiana, with plans to scale up production by 2026.
  • It also acquired Inversago Pharma and Embark Biotech in 2023, and pursued a major purchase of Catalent in 2024 to support mass manufacturing—actions reinforcing its platform growth for future therapeutic delivery capacity?

Numab Therapeutics

  • Leadership Change: In September 2025, Numab Therapeutics appointed Angehrn Pavik as its Chief Executive Officer, indicating a strategic leadership transition.
  • Strategic Acquisition: In May 2024, Numab's subsidiary, Yellow Jersey Therapeutics, was acquired by Johnson & Johnson for $1.25 billion. This acquisition includes the rights to NM26, a bi-specific antibody targeting atopic dermatitis, which is approaching Phase 2 clinical trials.

Proteintech Group, Inc.

  • AI Tool Launch: In September 2025, Proteintech launched "Able AI," an artificial intelligence tool aimed at accelerating scientific discovery by offering tailored product recommendations and support for experimental design.
  • 3D Epitope Mapping: In March 2025, Proteintech launched an innovative 3D epitope mapping tool, enabling researchers to interactively explore antibody binding sites.

Merck & Co., Inc.

  • Merck continues to be involved in the narcolepsy field through its previous development of suvorexant, the first FDA-approved orexin receptor antagonist for insomnia (approved in 2014). Although not specifically targeting narcolepsy, this involvement positions Merck among companies with expertise in the orexin system.
  • Merck is reportedly developing an oral orexin agonist, code-named MK-6552, which is currently in Phase 1 trials aimed at treating narcolepsy type 1.
  • In March 2022- Axsome Therapeutics Inc. and Jazz Pharmaceuticals entered into a legally binding agreement to buy Sunosi (solriamfetol), which is used to treat adult patients with excessive daytime sleepiness (EDS) brought on by narcolepsy or obstructive sleep apnea (OSA).

The primary factors affecting the growth of the narcolepsy market are an increase in the prevalence of narcolepsy and an increase in the number of obese individuals. Narcolepsy medications can be used to treat sleep apnea. Expanding disposable income and more knowledge of the benefits of narcolepsy medications are also projected to promote global market expansion. Since it has fewer negative effects than other stimulants, utilizing modafinil to treat patients also helps the drug's market expansion. Therefore, effective treatment can aid in preventing such ailments, propelling the narcolepsy market throughout the forecast period. Moreover, numerous local, regional, and international institutes, organizations, and councils work to spread awareness about narcolepsy-related problems and viable solutions. For instance, the non-profit group "Wake Up Narcolepsy" promotes public well-being by driving the hunt for a cure for disorders. To increase awareness and reduce social stigma among those who also experience the condition, Project Sleep, a non-profit organization with headquarters in the US, launched a program called "Rising Voices of Narcolepsy" that train those who have the condition to share their stories with their communities both verbally and in writing. In addition, the rapid acceptance of a novel therapy for the treatment of narcolepsy is predicted to boost the market. However, market growth is anticipated to be constrained by the side effects of narcolepsy drugs and the possibility of delayed diagnosis and treatment. The dearth of knowledge among patients and medical professionals in developed and emerging nations further restricts the market growth of narcolepsy. The government's stringent regulations governing the agreement for narcolepsy drugs are another factor anticipated to constrain market growth.

By Product Type

  • Mono-specific
    •  Monovalent
    •  Multivalent
    •  Bi-paratopic
  •  Multi-specific

By Indication

  • Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
  • Respiratory Syncytial Virus (RSV) Infection
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Oncology
  • Immune Mediated Inflammatory Diseases (IMID)
  • Psoriasis
  • chronic kidney diseases
  • Bone Disorders
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  •  Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

Here’s a regional view of where the most progress is happening

North America 

North America has a leading position in the global nanobodies market, with an estimated market share of 33.5% by 2025. The region is at the forefront of market development due to several key factors:

  • Rising rates of chronic diseases like cancer and autoimmune disorders are increasing the demand for nanobody treatments.
  • Strong presence of major pharmaceutical and biotech companies.
  • Robust clinical trial infrastructure and regulatory frameworks are in place. There is significant investment in research and development activities.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to inorganic activities like partnerships and collaborations, the North American nanobodies market is anticipated to maintain a dominant place during the forecast period. For instance, on April 29, 2021, Alphamab Oncology, a producer and developer of novel therapeutic drugs for the treatment of cancer, announced that it had collaborated with Pfizer Inc. on a clinical study to examine the efficiency and safety of KN046 (a recombinant humanized bispecific antibody) when used in combination with Inlyta (axitinib) as the first-line therapy for non-small cell lung cancer (NSCLC). Another factor fostering regional growth is the rising incidence of cancer and other chronic diseases.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Nanobodies Market By Product Type, By Indication, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Nanobodies MarketVariables, Trends and Scope

    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Nanobodies Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Nanobodies Market Analysis Tools

    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.   Nanobodies Market By Product Type Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Mono-specific
                1.1.Monovalent
                1.2.Multivalent
                1.3. Bi-paratopic
             2.Multi-specific

  • 8.  Nanobodies Market By Indication Historical Analysis and Forecast 2026-2036 (USD Million)

    •        1. Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
             2. Respiratory Syncytial Virus (RSV) Infection
             3. Rheumatoid Arthritis
             4. Systemic Lupus Erythematosus
             5. Oncology
             6. Immune Mediated Inflammatory Diseases (IMID)
             7. Psoriasis
             8. chronic kidney diseases
             9. Bone Disorders
             10. Others

  • 9.  Nanobodies Market, By Distribution Channel Historical Analysis and Forecast 2026-2036 (USD Million)

    •        1. Hospital Pharmacies
             2. Retail Pharmacies
             3. Online Pharmacies

  • 10.   North America Nanobodies Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 11.   Latin America Nanobodies Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 12.   Europe Nanobodies Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 13.   Asia Pacific Nanobodies Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 14.   Middle East and Africa Nanobodies Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Novo Nordisk A/S
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck & Co., Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Shire Plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Merck KGaA
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. AbbVie, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
            6. C.H. Boehringer Sohn AG & Ko. KG.
                 6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. AlpalifeB Inc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. GenScript
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GeneMedi
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Numab Therapeutics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
            12. Proteintech Group, Inc.
                 12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Confo Therapeutics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. GT Biopharma, Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
            15. CUSABIO TECHNOLOGY LLC
                 15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

FAQ


The Nanobodies Market Report provides a deep-dive analysis into the market's growth drivers, challenges, and opportunities. You can expect to receive detailed insights into the following:

  • Market size and growth trends
  • Technological advancements in the field of nanobodies
  • Competitive analysis of key players in the industry
  • Regulatory landscape influencing the market dynamics
  • Potential for various applications of nanobodies in therapeutic development
  • Strategic recommendations for stakeholders and new entrants

Whether you're an investor, a Biotech entrepreneur, a researcher, or involved in pharmaceutical development, the Nanobodies Market Forecast report can benefit you in several ways:

  1. Informed Decision-Making: With up-to-date market data, you can make knowledgeable decisions about where to allocate resources.
  2. Competitive Advantage: Gaining insights into the competitive landscape can help you identify unique opportunities and potential areas for expansion or innovation.
  3. Strategic Planning: Understanding market trends and forecasts helps in strategizing long-term plans and adapting to market shifts.
  4. Risk Mitigation: By identifying potential challenges and growth bottlenecks, the report can guide you in mitigating risks associated with market dynamics.
  5. Investment Analysis: For investors, the report offers a detailed assessment of the market's investment potential, guiding where and when to invest.

The report includes a variety of data, such as:

  • Market Size and Segmentation: This section provides details on the current market size and forecasts for growth in different segments.
  • Trends and Drivers: This section analyzes emerging trends and the drivers propelling the market forward, including technological innovation and the regulatory landscape.
  • Competitive Analysis: Profiles of leading companies in the industry, their market strategies, and comparative analysis.
  • Geographic Insights: Market breakdown by key geographic regions and discussion of region-specific dynamics.
  • Regulatory Framework: Information on the regulatory environment that could impact market growth and product approvals.

The current market share of nanobodies in the pharmaceutical industry is growing due to their potential therapeutic applications. While the exact market share can vary and should be confirmed with recent market research reports, the approval of nanobody-based drugs and ongoing clinical trials indicate a positive trend in the market acceptance and investment in nanobody technology.

The field of nanobody research is experiencing rapid growth, with several trends and developments to watch for. One significant area is the exploration of multispecific nanobodies, which can simultaneously bind to multiple targets. This can lead to more potent and effective treatments. Additionally, advances in synthetic biology and protein engineering are expected to result in enhanced nanobody variants with improved efficacy and safety profiles. Combined with increased investment and collaborative partnerships in the industry, these developments hint at an exciting future for nanobodies in pharmaceuticals.

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

Related Market

Nanomedicine for Drug Delivery Market

Read More

Nanomedical Devices and Therapeutics Market

Read More

Nanorobots Market

Read More

Nano Therapy Market

Read More

Healthcare Nanotechnology Market

Read More

Nano Biotechnology Market

Read More

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11